RBC Capital Reiterates Outperform on CVS Health, Maintains $68 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Ben Hendrix has reiterated an 'Outperform' rating for CVS Health, maintaining a price target of $68.
September 04, 2024 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its 'Outperform' rating for CVS Health, maintaining a price target of $68. This suggests confidence in CVS's future performance.
The reiteration of an 'Outperform' rating and a maintained price target of $68 by RBC Capital indicates a positive outlook for CVS Health. This can lead to increased investor confidence and potentially a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100